Sanofi celebrated the inauguration of its new digital manufacturing facility in Framingham, Massachusetts. The inauguration is marking one of the world's first digital facilities using intensified, continuous biologics production technology.
Paris/France — Sanofi's new facility in Framingham features leading-edge technology that connects the production process with research and development. This facility accelerates the recent transformation of the company's Industrial Affairs organization to focus on biologics-based therapies, in line with the transformation of the company's R&D pipeline.
The facility's advanced paperless and data-driven manufacturing technologies is expected to enable the company to achieve higher levels of productivity, agility, and flexibility, reducing the time it takes for products to move from the development labs to the manufacturing plant.
Framingham is the latest biologics manufacturing facility amongst a number of pilots, which are being accelerated across the Sanofi network. The innovations established at this facility are being rapidly deployed and standardized across the company. Framingham is the first “digitally born” facility while similar digital transformations are introduced in other legacy plants. Beyond Framingham, the company intends to move forward with digital transformation initiatives in Toronto (Canada), Suzano (Brazil), Waterford (Ireland), Sisteron (France), and Geel (Belgium).
The Framingham digital bio-manufacturing facility is part of Sanofi's integrated, cross-functional biologics hub in Framingham, Massachusetts. A critical global hub for more than 30 years, the campus offers co-location of all the infrastructure and activities required to speed the delivery of innovative new therapies to patients, from early stage research and process development through clinical and commercial manufacturing, including the key enabling functions of quality control and compliance, regulatory, engineering, supply chain, and learning and development.